Do analysts prefer NXL or NMTC?

NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 554.76%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 NeuroOne Medical Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts prefer NXL or IRIX?

IRIDEX has a consensus price target of $3.00, indicating a potential upside of 237.08%. Given IRIDEX's stronger consensus rating and higher possible upside, analysts plainly believe IRIDEX is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NXL or IRIX more profitable?

IRIDEX has a net margin of -6.88% compared to Nexalin Technology's net margin of -4,141.94%. IRIDEX's return on equity of 0.00% beat Nexalin Technology's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -4,141.94% -278.24% -218.42% IRIDEX -6.88% N/A -12.55%

Does the media prefer NXL or IRIX?

In the previous week, IRIDEX had 123 more articles in the media than Nexalin Technology. MarketBeat recorded 133 mentions for IRIDEX and 10 mentions for Nexalin Technology. IRIDEX's average media sentiment score of 0.82 beat Nexalin Technology's score of 0.46 indicating that IRIDEX is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IRIDEX 1 Very Positive mention(s) 21 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NDRA or NXL?

ENDRA Life Sciences currently has a consensus target price of $25.00, indicating a potential upside of 357.88%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nexalin Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer NXL or SINT?

Sintx Technologies has a consensus target price of $9.50, suggesting a potential upside of 350.24%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to NXL or SINT?

In the previous week, Sintx Technologies had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 12 mentions for Sintx Technologies and 10 mentions for Nexalin Technology. Sintx Technologies' average media sentiment score of 0.61 beat Nexalin Technology's score of 0.46 indicating that Sintx Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sintx Technologies 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NVNO or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Nexalin Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Nexalin Technology (NXL) Competitors

$3.63 -0.48 (-11.68%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.75 +0.12 (+3.31%)

As of 10/9/2026 07:56 PM Eastern

Compare

NXL vs. NMTC, IRIX, NDRA, SINT, and NVNO

Should you buy Nexalin Technology stock or one of its competitors? Nexalin Technology's main competitors and comparable companies include NeuroOne Medical Technologies (NMTC), IRIDEX (IRIX), ENDRA Life Sciences (NDRA), Sintx Technologies (SINT), and enVVeno Medical (NVNO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Nexalin Technology (NASDAQ:NXL) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 554.76%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

0.6% of Nexalin Technology shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nexalin Technology has a beta of 4.08, indicating that its share price is 308% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -71.50% compared to Nexalin Technology's net margin of -4,141.94%. NeuroOne Medical Technologies' return on equity of -128.12% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 10 mentions for Nexalin Technology. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Nexalin Technology's score of 0.46 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroOne Medical Technologies has higher revenue and earnings than Nexalin Technology. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$217.16K	12.27	-$8.22M	-$14.41	N/A
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A

Summary

NeuroOne Medical Technologies beats Nexalin Technology on 12 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to IRIDEX?

Nexalin Technology (NASDAQ:NXL) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, IRIDEX had 123 more articles in the media than Nexalin Technology. MarketBeat recorded 133 mentions for IRIDEX and 10 mentions for Nexalin Technology. IRIDEX's average media sentiment score of 0.82 beat Nexalin Technology's score of 0.46 indicating that IRIDEX is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IRIDEX	1 Very Positive mention(s)	21 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IRIDEX has higher revenue and earnings than Nexalin Technology. IRIDEX is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$217.16K	12.27	-$8.22M	-$14.41	N/A
IRIDEX	$52.67M	0.30	-$4.44M	-$0.20	N/A

IRIDEX has a net margin of -6.88% compared to Nexalin Technology's net margin of -4,141.94%. IRIDEX's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
IRIDEX	-6.88%	N/A	-12.55%

Nexalin Technology has a beta of 4.08, meaning that its share price is 308% more volatile than the broader market. Comparatively, IRIDEX has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

IRIDEX has a consensus price target of $3.00, indicating a potential upside of 237.08%. Given IRIDEX's stronger consensus rating and higher possible upside, analysts plainly believe IRIDEX is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.6% of Nexalin Technology shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by company insiders. Comparatively, 8.6% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

IRIDEX beats Nexalin Technology on 12 of the 16 factors compared between the two stocks.

How does Nexalin Technology compare to ENDRA Life Sciences?

ENDRA Life Sciences (NASDAQ:NDRA) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

ENDRA Life Sciences has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. ENDRA Life Sciences' return on equity of -246.34% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-246.34%	-150.81%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

ENDRA Life Sciences has higher earnings, but lower revenue than Nexalin Technology. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A
Nexalin Technology	$217.16K	12.27	-$8.22M	-$14.41	N/A

In the previous week, Nexalin Technology had 9 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 10 mentions for Nexalin Technology and 1 mentions for ENDRA Life Sciences. Nexalin Technology's average media sentiment score of 0.46 beat ENDRA Life Sciences' score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
ENDRA Life Sciences	Neutral
Nexalin Technology	Neutral

ENDRA Life Sciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4.08, suggesting that its stock price is 308% more volatile than the broader market.

ENDRA Life Sciences currently has a consensus target price of $25.00, indicating a potential upside of 357.88%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nexalin Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ENDRA Life Sciences beats Nexalin Technology on 9 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to Sintx Technologies?

Nexalin Technology (NASDAQ:NXL) and Sintx Technologies (NASDAQ:SINT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Sintx Technologies has a consensus target price of $9.50, suggesting a potential upside of 350.24%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

0.6% of Nexalin Technology shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 4.1% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sintx Technologies had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 12 mentions for Sintx Technologies and 10 mentions for Nexalin Technology. Sintx Technologies' average media sentiment score of 0.61 beat Nexalin Technology's score of 0.46 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sintx Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sintx Technologies has a net margin of -848.20% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
Sintx Technologies	-848.20%	-354.44%	-115.37%

Nexalin Technology has higher earnings, but lower revenue than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$217.16K	12.27	-$8.22M	-$14.41	N/A
Sintx Technologies	$1.02M	8.94	-$10.36M	-$4.91	N/A

Summary

Sintx Technologies beats Nexalin Technology on 10 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Nexalin Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

enVVeno Medical has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4.08, indicating that its stock price is 308% more volatile than the broader market.

enVVeno Medical has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. enVVeno Medical's return on equity of -62.28% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Nexalin Technology has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Nexalin Technology	$217.16K	12.27	-$8.22M	-$14.41	N/A

In the previous week, Nexalin Technology had 9 more articles in the media than enVVeno Medical. MarketBeat recorded 10 mentions for Nexalin Technology and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.51 beat Nexalin Technology's score of 0.46 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Overall Sentiment
enVVeno Medical	Positive
Nexalin Technology	Neutral

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

enVVeno Medical and Nexalin Technology tied by winning 7 of the 14 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.02M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-0.25	25.57	274.15	26.16
Price / Sales	12.27	83.25	635.98	113.06
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	0.60	5.93	11.21	6.34
Net Income	-$8.22M	$146.18M	$3.50B	$381.90M
7 Day Performance	-36.65%	-0.38%	-0.90%	-1.41%
1 Month Performance	-25.46%	-2.02%	-4.44%	-3.48%
1 Year Performance	-90.55%	5.08%	6.96%	1.16%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	1.313 of 5 stars	$3.63 -11.7%	N/A	-91.9%	$3.02M	$217.16K	N/A	8	News Coverage Gap Down
NMTC NeuroOne Medical Technologies	3.4134 of 5 stars	$1.09 -16.2%	$7.33 +572.8%	-81.9%	$11.84M	$9.47M	N/A	18	Short Interest Increase High Trading Volume
IRIX IRIDEX	2.8317 of 5 stars	$0.64 +2.4%	$3.00 +372.4%	-20.5%	$10.89M	$52.67M	N/A	108	Gap Up
NDRA ENDRA Life Sciences	2.4422 of 5 stars	$5.88 +1.4%	$25.00 +325.2%	-19.8%	$8.70M	N/A	N/A	11	Positive News
SINT Sintx Technologies	2.9114 of 5 stars	$2.03 +2.0%	$9.33 +359.8%	-51.5%	$8.60M	$1.09M	N/A	32	News Coverage Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. NMTC, IRIX, NDRA, SINT, and NVNO

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Summary

How does Nexalin Technology compare to IRIDEX?

Summary

How does Nexalin Technology compare to ENDRA Life Sciences?

Summary

How does Nexalin Technology compare to Sintx Technologies?

Summary

How does Nexalin Technology compare to enVVeno Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. NMTC, IRIX, NDRA, SINT, and NVNO

How does Nexalin Technology compare to NeuroOne Medical Technologies?

Do analysts prefer NXL or NMTC?

Do institutionals and insiders hold more shares of NXL or NMTC?

Which has more risk and volatility, NXL or NMTC?

Is NXL or NMTC more profitable?

Does the media refer more to NXL or NMTC?

Which has preferable earnings & valuation, NXL or NMTC?

Summary

How does Nexalin Technology compare to IRIDEX?

Does the media prefer NXL or IRIX?

Which has higher valuation and earnings, NXL or IRIX?

Is NXL or IRIX more profitable?

Which has more volatility & risk, NXL or IRIX?

Do analysts prefer NXL or IRIX?

Do insiders & institutionals believe in NXL or IRIX?

Summary

How does Nexalin Technology compare to ENDRA Life Sciences?

Is NDRA or NXL more profitable?

Which has higher earnings and valuation, NDRA or NXL?

Does the media prefer NDRA or NXL?

Which has more risk and volatility, NDRA or NXL?

Do analysts recommend NDRA or NXL?

Do insiders & institutionals believe in NDRA or NXL?

Summary

How does Nexalin Technology compare to Sintx Technologies?

Do analysts prefer NXL or SINT?

Do institutionals & insiders hold more shares of NXL or SINT?

Does the media refer more to NXL or SINT?

Is NXL or SINT more profitable?

Which has better valuation and earnings, NXL or SINT?

Summary

How does Nexalin Technology compare to enVVeno Medical?

Do analysts rate NVNO or NXL?

Which has more risk and volatility, NVNO or NXL?

Is NVNO or NXL more profitable?

Which has preferable valuation & earnings, NVNO or NXL?

Does the media prefer NVNO or NXL?

Do insiders and institutionals hold more shares of NVNO or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools